{
    "nct_id": "NCT05593445",
    "official_title": "A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus",
    "inclusion_criteria": "* Biopsy-proven LS in the anogenital area.\n* Baseline IGA score ≥ 2 for LS.\n* Baseline Itch NRS score ≥ 4 in anogenital area.\n* Willingness to avoid pregnancy.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants who do not have LS involving anogenital area.\n* Concurrent conditions and history of other diseases:\n\n  1. Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including: candidiasis, chlamydia trachomatis, trichomonas vaginalis, neisseria gonorrhoeae, bacterial vaginosis, or herpes simplex.\n  2. Have active genital/vulvar lesions at screening and Day 1, not related to LS\n  3. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before baseline.\n* Laboratory values outside of the protocol-defined criteria\n* Pregnant or lactating participants or those considering pregnancy during the period of their study participation..\n* Other exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}